Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Stacey Ruf, PhD; and John A. Szychowski, AAS, BS
Multiple sclerosis (MS) is a chronic, unpredictable disease of the central nervous system. It is thought to be an autoimmune disease in which the body’s immune system attacks the myelin sheath (material that surrounds and protects nerve cells), causing brain signals to be interrupted.1
Symptoms commonly include numbness in the limbs, muscle weakness, paralysis, and/or vision distortion or impairment. The exact cause of MS is unknown, and symptoms vary greatly from one person to another and for any one person over time. Most people afflicted with MS have a normal or near-normal life expectancy, and the majority of people with the disease do not become severely disabled.
Although there is still no cure for MS, various strategies are available to modify the disease course, treat exacerbations (also known as relapses, attacks, or flare-ups), manage symptoms, and improve physical function and safety. In combination, these treatments are designed to enhance the quality of life for people living with MS. An individual’s treatment needs are best identified in an ongoing collaboration between a knowledgeable physician and other members of the treatment team.2
Of the approximately 400,000 Americans who have MS1
Most are diagnosed between the ages of 20 and 50 years.
Roughly 5% are diagnosed before age 21 years (early onset).
Approximately 9.4% are diagnosed after age 50 years (late onset).
An estimated 2 to 3 times as many women as men have MS.
Until recently, all MS-specific drug treatments were administered subcutaneously or intravenously. But in January 2010, Ampyra (dalfampridine) received US Food and Drug Administration (FDA) approval as the first orally administered MS drug indicated to improve patient ambulation.3
The trend toward less intrusive administration methods has prompted development of several oral drugs in this space.
MS drug utilization had a significant impact on trend in the last few years, as discussed in previously published articles including the generational trend research and the recent Alzheimer’s utilization trend research.4,5
However, future class costs are projected to outpace those of prior years because of the expected March 2010 launch of Ampyra and because of double-digit growth in utilization for existing market drugs. In this article we discuss the impact of MS therapy (MST) on trend and MST utilizers’ contributions to total annual drug expenditures compared with contributions of the overall commercial population.METHODS
This retrospective analysis was conducted using 241.9 million prescription claims from CVS Caremark’s computerized database. The population identified for the study consisted of 23.2 million members across funded benefit prescription plans administered by CVS Caremark. The plan sponsors included Medicaid, national and local employers, health plans, managed care organizations, insurance companies, unions, and government agencies located throughout the United States with prescription claims for all months between January 1, 2008, and December 31, 2009.
The members had claims in 2008 and 2009, categorized by generation: GI Generation (age ≥83 years), Silent Generation (age 63-82 years), Baby Boomers (age 44-62 years), Generation X (age 30-43 years), Generation Y (age 18-29 years), and Generation Z (age ≤17 years).4 In addition to categorizing utilizers by age band, we also separated metrics by sex (Table 1).
The utilization trend was based on average days supply and gross cost (which includes both plan sponsor and member contributions), reported on a per member per month basis. Medicare Part D plans were excluded. The plan sponsors had average eligibility changes limited to within ±15% period over period.
Patients on MST were identified by using the product indicator for approved MS treatments, which includes all strengths and dosage forms of the following: Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Rebif (interferon beta-1a), Extavia (interferon beta-1b), and Tysabri (natalizumab). Novantrone (mitoxantrone) was not included in the analysis because of its approval and use as a cancer treatment.THERAPEUTIC CLASS BACKGROUNDIndications
Three primary types of injectable MS drugs are available: glatiramer acetate, interferon beta, and natalizumab (Table 2). Each type of drug commonly has a different effect on individual patients. As a result, some product switching may be necessary to find the drug with greatest efficacy.Current Therapies
Currently several disease-modifying medications are approved by the FDA for use in relapsing forms of MS (including secondary-progressive MS for those people who still are experiencing relapses). These drugs work to slow down the natural course of the disease and prevent recurring symptoms. More specifically, the medications reduce the number of days a person might be actively ill with an attack of symptoms; they reduce or even eliminate the accumulation of lesions, or damaged areas, within the central nervous system; and they appear to slow down the accumulation of disabilities. All class drugs have proven records of partial to substantial success. Unfortunately, none of the currently available disease-modifying drugs are approved for treating primary-progressive MS.
Side effects are common when taking any of the disease-modifying drugs for the treatment of MS, although these vary in nature and severity. As a result, compliance rates can vary, and discontinuation of therapy is not uncommon.6
Ampyra, approved in January 2010, is a (non–diseasemodifying) potassium channel blocker used to improve ambulation in MS patients and administered orally. It is awaiting market launch, expected in March 2010.IMPACT BY GENERATION
In 2009, 25,059 unique MST utilizers were identified based on prescription claim data, representing approximately 0.11% of the overall cohort population studied. More than 75% of utilizers were female and the majority were Baby Boomers, although Generation X represented 30% of the MST utilizers (Table 3).
The average age of the study commercial group was compared with 2005 US Census population estimates by age bands. According to the Census estimate, those aged 20 to 49 years comprised 42.8% of the population. The same population in the study cohort made up 41.3%.MARKET SHARE
PDF is available on the last page.